Aspirin is being trialled as part of a potential new treatment for an aggressive form of breast cancer.
Researchers hope the cheap and widely available drug could work well when combined with immunotherapy for patients with triple negative breast cancer.
The trial, funded by the Breast Cancer Now Catalyst Programme, which aims to speed up progress in research through innovation and collaboration, is the first clinical study to test if aspirin can make tumours more sensitive to immunotherapy in these patients.
READ MORE: University of Edinburgh scientists successfully test cancer-killing ‘Trojan Horse’ drug
The research, led by Dr Anne Armstrong from the Christie NHS Foundation Trust in Manchester, will trial the drug avelumab both with and without aspirin before patients receive surgery and chemotherapy treatment.
Breast Cancer Now said successful results could lead to further clinical trials of aspirin and avelumab for incurable secondary triple negative breast cancer, which happens when cancer cells that started in the breast spread to other parts of the body.
There are around 8,000 women diagnosed with triple negative breast cancer in the UK each year, the charity said.
It is a less common but often more aggressive type of breast cancer that disproportionately affects younger women and black women, the organisation added.
Dr Armstrong, a consultant medical oncologist and honorary senior lecturer at the Christie NHS Foundation Trust, said: “Our earlier research has suggested that aspirin can make certain types of immunotherapy more effective by preventing the cancer from making substances that weaken the immune response.
“Anti-inflammatory drugs like aspirin could hold the key to increasing the effectiveness of immunotherapy when used at the same time.
“Trialling the use of a drug like aspirin is exciting because it is so widely available and inexpensive to produce.
“We hope our trial will show that, when combined with immunotherapy, aspirin can enhance its effects and may ultimately provide a safe new way to treat breast cancer.”
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: “The 8,000 women diagnosed with triple negative breast cancer in the UK each year face the frightening reality of limited treatment options – we urgently need to address this.
READ MORE: SNP urged to focus on clearing record-high waiting list for cancer patients
“Research has already suggested aspirin could improve outcomes for many cancer patients and we hope that Dr Armstrong’s trial will show the same to be true for patients with triple negative breast cancer, so that we can prevent more lives being lost to this devastating disease.”
Breast Cancer Now said pharmaceutical giant Pfizer has provided the charity with funding through an independent medical research grant and given its researchers access to several Pfizer medicines.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here